A pet-built CGM enters Canada and tests Abbott's off-label moat

A continuous glucose monitor purpose-built for cats and dogs went on sale in Canada this week. It is the first pet-specific CGM on the North American market, and a direct commercial test of whether vets switch from the human-built Freestyle Libre they have been using off-label for years. The technology question is mostly settled. The operator question is workflow, price, and distribution.

ALR launches GluCurve Pet CGM in Canada, 14-day wear, vet portal included

ALR Technologies SG Ltd. (OTC: ALRTF), a small-cap diabetes-management company, announced that the GluCurve Pet CGM is now available in Canada through veterinary distribution. The product is the first continuous glucose monitor designed specifically for diabetic cats and dogs, rather than a human CGM adapted off-label for veterinary use.

The sensor adheres to the pet, reads interstitial glucose every three minutes, and lasts up to 14 days per application, per ALR's product page. Owners view live readings inside the GluCurve app, and the same data streams to the ALRT Veterinary Web Portal — the piece vets actually care about — where the practice can adjust insulin remotely.

ALR has telegraphed this launch for several months. The Canadian go-live had been scheduled for January 2026 and slipped into the spring, per dvm360. The company has said the US relaunch will follow in the second quarter of 2026 through a "leading veterinary distributor" it has not yet publicly named, with EU, Asia-Pacific, and Latin America to follow.

Pricing is positioned below two reference points the press release explicitly calls out: traditional in-clinic glucose curves, and human CGMs used off-label. ALR has not disclosed a specific list price.

The addressable population is real but not enormous. Roughly 1 in 300 dogs and cats is diagnosed with diabetes, per Veterinary Medicine at Illinois. The opportunity is not the device sale; it is the recurring sensor refill and the workflow lock-in inside the clinic.

The real asset is the vet portal, not the sensor

Sensor accuracy isn't the unlock. Vets already trust Freestyle Libre data on pets, and several peer-reviewed studies have shown the human Libre performs adequately on dogs and cats across normal and high glucose ranges. The clinical question got answered years ago.

The operator question is whether GluCurve replaces a working off-label workflow. That depends on three things — and the device itself is the least important of them.

The first is the vet web portal. Off-label Libre use forces the vet to either ask the owner to share screenshots from a consumer app, or to set up a workaround using Abbott's LibreView. Neither is a clean clinical workflow. A vet-purpose portal with case management, insulin-dose adjustment tooling, and patient history is the asset ALR is selling — the sensor is the data source. If the portal is good, GluCurve becomes the spine of a diabetic-pet practice, not just a monitor.

The second is price. Off-label Libre runs roughly USD 60–80 per sensor at retail pharmacies in the US, and slightly less in Canada. Whatever GluCurve charges per sensor sets the ceiling for displacing Libre. If GluCurve lands materially below that — and ALR's "competitively priced" framing implies it does — vets have a reason to switch. If it lands at parity, switching costs and incumbent comfort win.

The third is distribution. The unnamed US distributor matters enormously. A tier-one veterinary distributor (Covetrus, Patterson, MWI) plus a sales force already in clinics is the difference between a real launch and a press release. ALR is a micro-cap with limited commercial muscle of its own; the distribution partner is the de facto commercial engine.

The competitive overhang is Abbott. Freestyle Libre is FDA-approved for humans and off-label for pets, which has worked for Abbott — no veterinary-specific clinical trial costs, no veterinary regulatory path, demand happens anyway. If ALR proves there is a paying market for a pet-built CGM, Abbott has the choice of officially entering the category, partnering, or staying off-label. None of those outcomes are bad for the category. All of them are bad for ALR if Abbott moves.

Beyond GluCurve specifically, the bigger pattern is more interesting. This is the first commercial purpose-built medical device for pets in the CGM class. Most of "pet medtech" so far has been human devices adapted off-label — Libre, pulse oximeters, ECG patches, ultrasound. If GluCurve proves a clinic and an owner will pay for a pet-purpose version of a device that already works off-label, the read-across to pet-specific pulse oximetry, blood-pressure monitoring, and wearable cardiac monitoring is direct.

What the US Q2 launch reveals about the category

The Canadian launch is a soft open. The signals worth watching are six weeks away.

The US distributor name. A Covetrus, Patterson, or MWI tag means GluCurve gets into clinic procurement quickly and at scale. A second-tier distributor signals ALR could not land a tier-one partner, which is a commercial-strength tell.

US list price. The pricing gap to Freestyle Libre is the single largest determinant of switching. Sensor price plus portal subscription, if any, is the number to track.

Abbott's response. Abbott has historically said little about off-label veterinary Libre use. If GluCurve gains real traction, expect either an Abbott-branded veterinary line or a quiet pricing move. If Abbott goes silent and prices stay flat, ALR has room.

Reimbursement and pet insurance coverage. Trupanion, MetLife Pet, and Embrace cover diabetes management to varying degrees. Whether the major US pet insurers add GluCurve to covered devices changes the consumer math significantly.

Clinic adoption pattern. The early-adopter clinics will be the ones already running off-label Libre. Watch whether independent practices move first, or whether corporate consolidators (Mars-VCA, NVA, Thrive) standardize on it. Corporate standardization would compress the timeline meaningfully.

GluCurve in Canada is interesting. GluCurve in a US clinic with a tier-one distributor name and a price 20% below off-label Libre would be a category event. That data point is coming inside the next quarter.

Source: ALR Technologies has launched the GluCurve Pet CGM in Canada, via PR Newswire